EHA 2021 | Liposomal daunorubicin and cytarabine in R/R ALL
Bijal Shah, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses a Phase II pilot study investigating CPX-351, a dual-drug liposomal encapsulation of cytarabine and daunorubicin, in adults with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). CPX-351 is currently approved for acute myeloid leukemia (AML). During its pre-clinical development, it showed clinical efficacy in not only AML, but also ALL. Many ALL patients enrolled in this study had failed previous immunotherapeutic approaches, including CAR T-cell therapy, blinatumomab, and inotuzumab. Among nine evaluable patients, three patients achieved a complete remission (CR) or complete composite remission (CRi). In patients who did not achieve a CR or CRi, there was significant blast reduction with hematologic recovery and increased time to subsequent therapy. Overall, the drug was well tolerated. The median progression-free survival observed was 28 days, and the median overall survival was approximately 6 months. Dr Shah outlines potential therapeutic strategies that combine CPX-351 with other therapies such as venetoclax. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Bijal Shah, MD, has received research funding from Kite/Gilead and Jazz Pharmaceuticals; has participated in an advisory role with Kite/Gilead, BMS/Celgene, Novartis, Precision Biomedicines, Adaptive, Jazz Pharma, Servier, AstraZeneca and Beigene.
